Form D · Biotechnology
Icosavax, Inc.
Seattle, WA · CIK 0001786255
Offering snapshot reported Apr 7, 2021 · SEC filing
- Reported sold
- $99.7M Offering amount: $99.7M
- Investors reported
- Not reported Form D · investor count
- Minimum accepted
- Not reported Reported outside-investor minimum
- First sale
- Not reported As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 7, 2021 | Initial | $99,729,701 | No comparison | Not reported | SEC filing |
| Oct 18, 2019 | Initial | $30,007,376 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Not reported
- Exemptions
- Not reported
- Duration over one year
- Not reported
- Business combination
- Not reported
- Sales commissions
- Not reported
- Finders' fees
- Not reported
- Form D file number
- 021-394949
Source: Form D, filed Apr 7, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cassia Cearley | Executive |
| Terry Gould | Director |
| Jason Hafler | Director |
| Douglas A. Holtzman | Executive |
| Niranjan Kanesa Thasan | Executive |
| Peter Kolchinsky | Director |
| Mark Mc Dade | Director |
| Eric Moessinger | Director |
| Charles Richardson | Executive |
| Adam K. Simpson | Director, Executive |
| Tadataka Yamada, M.D. | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Ave. E, Ste. 208
Seattle, WA, 98102
Seattle, WA, 98102